{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:51:05Z","timestamp":1791517865399,"version":"4.3.4"},"reference-count":68,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Treatment efficacy in Crohn's disease (CD) may vary according to disease location. We aimed to evaluate the long-term efficacy of biological and small molecule therapies in moderate-to-severe luminal CD stratified by CD location.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We conducted a systematic review and Bayesian network meta-analysis (NMA) of randomized controlled trials (RCTs) in adults (aged \u226518\u2009years) with moderate-to-severe CD (Crohn\u2019s Disease Activity Index [CDAI] 220-450), identified through PubMed, Embase, and CENTRAL to August 12, 2025. Predefined outcomes included clinical remission (CDAI &amp;lt; 150) and endoscopic response (\u226550% reduction in Simple Endoscopic Score-CD (SES-CD) at week 52 (range, 44-56 weeks), stratified by Montreal disease location and trial design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen RCTs (including 4697 patients) evaluating adalimumab, infliximab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, and upadacitinib were included. Clinical remission rates were lowest in isolated ileal disease, and only guselkumab regimens (200\u2009mg\/100\u2009mg: relative risk, 3.4 [95% CI, 1.3-8.9]) were statistically superior to placebo for maintenance of clinical remission at week 52. In isolated colonic disease, upadacitinib 30\u2009mg ranked highest in re-randomized trials and with significant location-dependent differences (efficacy ratio [EF] for colonic vs ileal is 4.6 [95% CI, 1.7-12.6], EF for ileocolonic vs ileal is 3.45 [95% CI, 1.2-9.6]), consistent with endoscopic response rates. No location-dependent differences were observed for other agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Relative efficacy of advanced therapies in luminal CD varied by disease location. These findings support consideration of disease location in personalized treatment decision-making to improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag177","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:32:04Z","timestamp":1787052724000},"source":"Crossref","is-referenced-by-count":0,"title":["Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's\u00a0disease: a systematic review and network meta-analysis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8994-502X","authenticated-orcid":false,"given":"S\u00f3ley Poulsen","family":"Dalsgar\u00f0","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital\u2014Herlev and Gentofte , DK-2730, Herlev,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1893-2287","authenticated-orcid":false,"given":"Kavini Kalinga Bandara","family":"Pkb","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital\u2014Herlev and Gentofte , DK-2730, Herlev,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-7966","authenticated-orcid":false,"given":"Jakob Benedict","family":"Seidelin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital\u2014Herlev and Gentofte , DK-2730, Herlev,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-3889","authenticated-orcid":false,"given":"Jacob Tveiten","family":"Bjerrum","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital\u2014Herlev and Gentofte , DK-2730, Herlev,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-7030","authenticated-orcid":false,"given":"Mohamed","family":"Attauabi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital\u2014Herlev and Gentofte , DK-2730, Herlev,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100823332115800_izag177-B1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2026100823332115800_izag177-B2","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.14309\/ajg.0000000000002687","article-title":"Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis","volume":"119","author":"Coward","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2026100823332115800_izag177-B3","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1136\/gutjnl-2019-318936","article-title":"IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology","volume":"68","author":"Jones","year":"2019","journal-title":"Gut"},{"key":"2026100823332115800_izag177-B4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2026100823332115800_izag177-B5","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"2026100823332115800_izag177-B6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1053\/j.gastro.2025.09.038","article-title":"AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn\u2019s disease","volume":"169","author":"Scott","year":"2025","journal-title":"Gastroenterology"},{"key":"2026100823332115800_izag177-B7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med."},{"key":"2026100823332115800_izag177-B8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"2026100823332115800_izag177-B9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med."},{"key":"2026100823332115800_izag177-B10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn\u2019s disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"key":"2026100823332115800_izag177-B12","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"2026100823332115800_izag177-B13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/nejmoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med."},{"key":"2026100823332115800_izag177-B14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"2026100823332115800_izag177-B15","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet."},{"key":"2026100823332115800_izag177-B16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2468-1253(23)00356-4","article-title":"Guselkumab in Crohn\u2019s disease: the IL-23 race continues","volume":"9","author":"Fumery","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B17","doi-asserted-by":"publisher","first-page":"i048","DOI":"10.1093\/ecco-jcc\/jjab232.039","article-title":"OP40 Efficacy of risankizumab induction and maintenance therapy by baseline Crohn\u2019s Disease location: post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"16","author":"Bossuyt","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026100823332115800_izag177-B18","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med."},{"key":"2026100823332115800_izag177-B19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1053\/gast.2002.32413","article-title":"The molecular classification of the clinical manifestations of Crohn\u2019s disease","volume":"122","author":"Ahmad","year":"2002","journal-title":"Gastroenterology"},{"key":"2026100823332115800_izag177-B20","doi-asserted-by":"publisher","first-page":"100097","DOI":"10.1016\/j.crphar.2022.100097","article-title":"Ileal and colonic Crohn\u2019s disease: does location makes a difference in therapy efficacy?","volume":"3","author":"Atreya","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov."},{"key":"2026100823332115800_izag177-B21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/MIB.0000000000000662","article-title":"Distinct microbiotas are associated with ileum-restricted and colon-involving Crohn\u2019s disease","volume":"22","author":"Naftali","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2026100823332115800_izag177-B22","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41575-021-00424-6","article-title":"Location is important: differentiation between ileal and colonic Crohn\u2019s disease","volume":"18","author":"Atreya","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn\u2019s disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"Cleynen","year":"2016","journal-title":"Lancet."},{"key":"2026100823332115800_izag177-B25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312673","article-title":"Recent advances in clinical practice: a systematic review of isolated colonic Crohn&#039; s disease: the third IBD?","volume":"66","author":"Subramanian","year":"2017","journal-title":"Gut"},{"key":"2026100823332115800_izag177-B26","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.cgh.2024.05.013","article-title":"Sex-related differences in the phenotype and course of inflammatory bowel disease: SEXEII study of ENEIDA","volume":"22","author":"Gargallo-Puyuelo","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B27","doi-asserted-by":"publisher","first-page":"1756284820915043","DOI":"10.1177\/1756284820915043","article-title":"Sex-based differences in inflammatory bowel diseases: a review","volume":"13","author":"Rustgi","year":"2020","journal-title":"Ther Adv Gastroenterol."},{"key":"2026100823332115800_izag177-B28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1053\/j.gastro.2025.08.032","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe Crohn\u2019s disease: 2025 AGA evidence synthesis","volume":"169","author":"Singh","year":"2025","journal-title":"Gastroenterology"},{"key":"2026100823332115800_izag177-B29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"2026100823332115800_izag177-B30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/apt.18110","article-title":"Network meta-analysis: comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease","volume":"60","author":"Attauabi","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"key":"2026100823332115800_izag177-B32","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"key":"2026100823332115800_izag177-B33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"2026100823332115800_izag177-B34","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026100823332115800_izag177-B35","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.cgh.2024.06.048","article-title":"AGA clinical practice update on endoscopic scoring systems in inflammatory bowel disease: commentary","volume":"22","author":"Buchner","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/0272989X13485156","article-title":"Evidence synthesis for decision making 7: a reviewer\u2019s checklist","volume":"33","author":"Ades","year":"2013","journal-title":"Med Decis Making."},{"key":"2026100823332115800_izag177-B37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making."},{"key":"2026100823332115800_izag177-B38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods."},{"key":"2026100823332115800_izag177-B39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","article-title":"Adalimumab induces deep remission in patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/ecco-jcc\/jjw178","article-title":"Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn\u2019s disease: results from the EXTEND trial","volume":"11","author":"Reinisch","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2026100823332115800_izag177-B41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"2026100823332115800_izag177-B42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/ibd\/izae200","article-title":"Induction of endoscopic response, remission, and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes and quality of life in patients with Crohn\u2019s disease","volume":"31","author":"Pan\u00e9s","year":"2025","journal-title":"Inflamm Bowel Dis."},{"key":"2026100823332115800_izag177-B43","doi-asserted-by":"publisher","first-page":"i156","DOI":"10.1093\/ecco-jcc\/jjad212.0087","article-title":"DOP47 Characterisation of endoscopic improvement in Crohn\u2019s Disease with upadacitinib treatment","volume":"18","author":"Panaccione","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026100823332115800_izag177-B44","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.cgh.2023.11.010","article-title":"Effects of mirikizumab on histologic resolution of Crohn\u2019s disease in a randomized controlled phase 2 trial","volume":"22","author":"Magro","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2026100823332115800_izag177-B46","doi-asserted-by":"publisher","first-page":"i1378","DOI":"10.1093\/ecco-jcc\/jjad212.0871","article-title":"P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn\u2019s disease","volume":"18","author":"Reinisch","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026100823332115800_izag177-B47","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"2026100823332115800_izag177-B48","doi-asserted-by":"publisher","first-page":"i1372","DOI":"10.1093\/ecco-jcc\/jjae190.0876","article-title":"P0702 Efficacy of subcutaneous infliximab maintenance therapy according to disease location in patients with moderate-to-severe Crohn\u2019s disease: a post hoc analysis of the Phase 3 LIBERTY-CD study","volume":"19","author":"Schreiber","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026100823332115800_izag177-B49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet."},{"key":"2026100823332115800_izag177-B50","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet."},{"key":"2026100823332115800_izag177-B51","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.14309\/ajg.0000000000001795","article-title":"Comparative effectiveness of biologics for endoscopic healing of the ileum and colon in Crohn\u2019s disease","volume":"117","author":"Narula","year":"2022","journal-title":"Am J Gastroenterol."},{"key":"2026100823332115800_izag177-B52","doi-asserted-by":"publisher","author":"Jairath V","DOI":"10.14309\/01.ajg.0001034688.99618.b9"},{"key":"2026100823332115800_izag177-B53","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.14309\/ajg.0000000000000617","article-title":"Ileal and rectal ulcer size affects the ability to achieve endoscopic remission: a post hoc analysis of the SONIC trial","volume":"115","author":"Narula","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"2026100823332115800_izag177-B54","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"key":"2026100823332115800_izag177-B55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B56","doi-asserted-by":"publisher","first-page":"jjae113","DOI":"10.1093\/ecco-jcc\/jjae113","article-title":"Re-evaluating methods for assessing differences in response in ileal vs colonic Crohn\u2019s disease: a post-hoc analysis of the FITZROY trial","volume":"19","author":"Ma","year":"2025","journal-title":"J Crohns Colitis."},{"key":"2026100823332115800_izag177-B57","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/gut.32.9.1071","article-title":"Double blind, placebo controlled trial of metronidazole in Crohn\u2019s disease","volume":"32","author":"Sutherland","year":"1991","journal-title":"Gut"},{"key":"2026100823332115800_izag177-B58","doi-asserted-by":"publisher","first-page":"622934","DOI":"10.3389\/fimmu.2021.622934","article-title":"Role of the IL23\/IL17 pathway in Crohn\u2019s disease","volume":"12","author":"Schmitt","year":"2021","journal-title":"Front Immunol."},{"key":"2026100823332115800_izag177-B59","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/apt.16536","article-title":"Review article: distinctions between ileal and colonic Crohn\u2019s disease: from physiology to pathology","volume":"54","author":"Pierre","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2026100823332115800_izag177-B60","doi-asserted-by":"publisher","first-page":"18129","DOI":"10.1073\/pnas.0505256102","article-title":"Reduced paneth cell \u03b1-defensins in ileal Crohn\u2019s disease","volume":"102","author":"Wehkamp","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"key":"2026100823332115800_izag177-B61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2172-11-61","article-title":"Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease","volume":"11","author":"Bogaert","year":"2010","journal-title":"BMC Immunol."},{"key":"2026100823332115800_izag177-B62","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ibd\/izz241","article-title":"Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn\u2019s disease","volume":"26","author":"Lewis","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2026100823332115800_izag177-B63","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1016\/j.cgh.2023.05.029","article-title":"Standardizing scoring conventions for Crohn\u2019s disease endoscopy: an international RAND\/UCLA appropriateness study","volume":"21","author":"Khanna","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B64","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cgh.2024.12.040","article-title":"Comparative effectiveness of infliximab vs ustekinumab for endoscopic and transmural remission in biologic na\u00efve Crohn\u2019s disease","volume":"24","author":"Huang","year":"2026","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026100823332115800_izag177-B65","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12876-022-02280-3","article-title":"Long-term effectiveness and safety of ustekinumab in bio-na\u00efve and bio-experienced anti-tumor necrosis factor patients with Crohn\u2019s disease: a real-world multicenter Brazilian study","volume":"22","author":"Parra","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"2026100823332115800_izag177-B66","doi-asserted-by":"publisher","first-page":"otae059","DOI":"10.1093\/crocol\/otae059","article-title":"Real-world ustekinumab experience in ileum-dominant versus colonic Crohn\u2019s disease","volume":"6","author":"Vien","year":"2024","journal-title":"Crohns Colitis 360."},{"key":"2026100823332115800_izag177-B67","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2026100823332115800_izag177-B68","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.cgh.2025.07.009","article-title":"Efficacy of advanced therapies in achieving remission by disease location in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"24","author":"Lee","year":"2026","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag177\/71734976\/izag177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag177\/71734976\/izag177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:33:34Z","timestamp":1791516814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag177\/8889165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":68,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag177","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"article-number":"izag177"}}